Biogen executives sought to assure investors that the science behind its newly approved Alzheimer’s disease drug is firm despite ongoing questions about whether the drug works, how it was approved, ...

Woods noted that Biogen has multiple focuses across autoimmune kidney diseases and Alzheimer’s, unlike many names in the ...

Biogen discontinues Apellis programs post $5.6B acquisition, reallocating resources to Empaveli and Syfovre. U.S. begins ...

This delay is attributed to procedural issues at the European Medicines Agency that have implications for the review process of lecanemab. Lecanemab has been under EMA review since January 2023 for ...

Following weeks of fiery criticism for its wide-labeled approval for Biogen’s Aduhelm for anyone with Alzheimer’s disease, the FDA is now narrowing the recommended window of patients to only those ...

A report by two House committees questioned the approval process for an Alzheimer’s drug produced by Biogen. Congressional investigators called the Food and Drug Administration’s process "rife with ...

The Food and Drug Administration’s approval process for Biogen’s controversial Alzheimer’s drug was “rife with irregularities,” a report from House Democrats concluded. The FDA’s collaboration with ...